805 research outputs found

    Determining the Roles of MYB Family Transcription Factors in Breast Tumorigenesis

    Get PDF
    A major advancement in the field of breast cancer research was the discovery of the breast tumor intrinsic subtypes made through the utilization of gene expression microarrays. Breast cancer can no longer be viewed as a single disease, but rather as at least five different diseases each with unique biological activity and clinical outcomes. Targeted therapy strategies are now employed to treat the different tumor types, such as estrogen receptor modulators for ER-positive disease, and HER2-inhibitors for the treatment of HER2-positive tumors. For tumors lacking therapeutic targets, patients are limited to cytotoxic chemotherapy regimens. Consequently, additional research is crucial in further elucidating the molecular pathways governing each breast tumor subtype. Over one thousand genes are used to stratify the intrinsic molecular subtypes; however, very few of these genes have been analyzed for their direct role in tumorigenesis. This dissertation focuses on investigating two intrinsic genes, B-Myb and c-Myb, which are both members of an evolutionarily conserved gene family first identified as transforming genes in avian viruses. B-Myb is highly expressed in basal-like tumors, whereas c-Myb is highly expressed in luminal tumors. We applied in vitro and in vivo analyses to ascertain the roles of these genes within the molecular subtypes. High B-Myb expression levels were predictive of poor outcomes across all breast tumors and within subtypes. Mammary epithelial cells expressing high levels of B-Myb were more sensitive to topoisomerase 2α inhibitors, but not other chemotherapeutics, via the induction of G2/M cell cycle genes including TOP2A itself. We identified the first published B-Myb germline variant causing an increased risk for basal-like disease. We found that the c-Myb oncogene was behaving as a tumor suppressor in luminal breast cancer through a novel p53 stabilization pathway. These results have significant treatment implications in light of an ongoing hematologic malignancies clinical trial in which c-Myb is targeted for knock-down through antisense oligonucleotides. These results point to both B-Myb and c-Myb as important breast cancer biomarkers with potential clinical importance for determining disease risk and guiding treatment, and provide important insight into the roles of MYB family proteins in the etiology of breast cancer

    Potential Tumor Suppressor Role for the c-Myb Oncogene in Luminal Breast Cancer

    Get PDF
    The transcription factor c-Myb has been well characterized as an oncogene in several human tumor types, and its expression in the hematopoietic stem/progenitor cell population is essential for proper hematopoiesis. However, the role of c-Myb in mammopoeisis and breast tumorigenesis is poorly understood, despite its high expression in the majority of breast cancer cases (60-80%).We find that c-Myb high expression in human breast tumors correlates with the luminal/ER+ phenotype and a good prognosis. Stable RNAi knock-down of endogenous c-Myb in the MCF7 luminal breast tumor cell line increased tumorigenesis both in vitro and in vivo, suggesting a possible tumor suppressor role in luminal breast cancer. We created a mammary-derived c-Myb expression signature, comprised of both direct and indirect c-Myb target genes, and found it to be highly correlated with a published mature luminal mammary cell signature and least correlated with a mammary stem/progenitor lineage gene signature.These data describe, for the first time, a possible tumor suppressor role for the c-Myb proto-oncogene in breast cancer that has implications for the understanding of luminal tumorigenesis and for guiding treatment

    Absence of erythrocyte sequestration in a case of babesiosis in a splenectomized human patient

    Get PDF
    BACKGROUND: The importance of vascular occlusion in the pathogenesis of human haemoprotozoal disease is unresolved. METHODS: Giemsa-stained tissue sections from a human case of Babesia microti infection in a splenectomized patient with chronic lymphocytic leukaemia and colon cancer were examined to ascertain the distribution of parasitized erythrocytes within the vascular lumen. RESULTS: No evidence of sequestration was observed. CONCLUSION: This first report on the vascular location of B. microti in human tissue suggests that severe multi-organ failure due to babesiosis is independent of sequestration of parasitized erythrocytes. A similar pathogenesis may also cause multi-organ failure in other intraerythrocytic protozoal infections, including falciparum malaria

    Prolactin

    Get PDF
    During an oral glucose tolerance test (OGTT) glucose and insulin levels were measured in 26 patients with prolactin-producing pituitary tumours without growth hormone excess. Basal glucose and insulin levels did not differ from the values of an age-matched control group. After glucose load the hyperprolactinaemic patients showed a decrease in glucose tolerance and a hyperinsulinaemia. Bromocriptine (CB 154), which suppressed PRL, improved glucose tolerance and decreased insulin towards normal in a second OGTT. — Human PRL or CB 154 had no significant influence on insulin release due to glucose in the perfused rat pancreas. — These findings suggest a diabetogenic effect of PRL. CB 154 might be a useful drug in improving glucose utilization in hormone-active pituitary tumours

    Studying Cat (Felis catus) Diabetes: Beware of the Acromegalic Imposter

    Get PDF
    Naturally occurring diabetes mellitus (DM) is common in domestic cats (Felis catus). It has been proposed as a model for human Type 2 DM given many shared features. Small case studies demonstrate feline DM also occurs as a result of insulin resistance due to a somatotrophinoma. The current study estimates the prevalence of hypersomatotropism or acromegaly in the largest cohort of diabetic cats to date, evaluates clinical presentation and ease of recognition. Diabetic cats were screened for hypersomatotropism using serum total insulin-like growth factor-1 (IGF-1; radioimmunoassay), followed by further evaluation of a subset of cases with suggestive IGF-1 (>1000 ng/ml) through pituitary imaging and/ or histopathology. Clinicians indicated pre-test suspicion for hypersomatotropism. In total 1221 diabetic cats were screened; 319 (26.1%) demonstrated a serum IGF-1>1000 ng/ml (95% confidence interval: 23.6-28.6%). Of these cats a subset of 63 (20%) underwent pituitary imaging and 56/63 (89%) had a pituitary tumour on computed tomography; an additional three on magnetic resonance imaging and one on necropsy. These data suggest a positive predictive value of serum IGF-1 for hypersomatotropism of 95% (95% confidence interval: 90-100%), thus suggesting the overall hypersomatotropism prevalence among UK diabetic cats to be 24.8% (95% confidence interval: 21.2-28.6%). Only 24% of clinicians indicated a strong pre-test suspicion; most hypersomatotropism cats did not display typical phenotypical acromegaly signs. The current data suggest hypersomatotropism screening should be considered when studying diabetic cats and opportunities exist for comparative acromegaly research, especially in light of the many detected communalities with the human disease

    In vitro and in vivo analysis of B-Myb in basal-like breast cancer

    Get PDF
    A defining feature of basal-like breast cancer, a breast cancer subtype with poor clinical prognosis, is the high expression of “proliferation signature” genes. We identified B-Myb, a MYB family transcription factor that is often amplified and overexpressed in many tumor types, as being highly expressed in the proliferation signature. However, the roles of B-Myb in disease progression, and its mammary-specific transcriptional targets, are poorly understood. Here, we demonstrated that B-Myb expression is a significant predictor of survival and pathological complete response to neoadjuvant chemotherapy in breast cancer patients. We also identified a significant association between the G/G genotype of a nonsynonymous B-Myb germline variant (rs2070235, S427G) and an increased risk of basal-like breast cancer [OR 2.0, 95% CI (1.1-3.8)]. In immortalized, human mammary epithelial cell lines, but not basal-like tumor lines, cells ectopically expressing wild-type B-Myb or the S427G variant showed increased sensitivity to two DNA topoisomerase IIα inhibitors, but not to other chemotherapeutics. In addition, microarray analyses identified many G2/M genes as being induced in B-Myb overexpressing cells. These results confirm that B-Myb is involved in cell cycle control, and that dysregulation of B-Myb may contribute to increased sensitivity to a specific class of chemotherapeutic agents. These data provide insight into the influence of B-Myb in human breast cancer, which is of potential clinical importance for determining disease risk and for guiding treatment
    corecore